Conjugated estrogens/bazedoxifene

Conjugated estrogens/bazedoxifene
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vignesh Ponnusamy, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

WARNING See full prescribing information for complete Boxed Warning. ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA: Women taking DUAVEE should not take additional estrogens There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens Estrogen therapy should not be used for the prevention of cardiovascular disease or dementia The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Overview

Conjugated estrogens/bazedoxifene is a combination of conjugated estrogens with an estrogen agonist/antagonist that is FDA approved for the {{{indicationType}}} of moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis. There is a Black Box Warning for this drug as shown here. Common adverse reactions include muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition1

• Dosing Information

• Dosage

Condition2

• Dosing Information

• Dosage

Condition3

• Dosing Information

• Dosage

Condition4

• Dosing Information

• Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1

• Developed by:

• Class of Recommendation:

• Strength of Evidence:

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Conjugated estrogens/bazedoxifene in adult patients.

Non–Guideline-Supported Use

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Conjugated estrogens/bazedoxifene in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding FDA-Labeled Use of Conjugated estrogens/bazedoxifene in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1

• Developed by:

• Class of Recommendation:

• Strength of Evidence:

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Conjugated estrogens/bazedoxifene in pediatric patients.

Non–Guideline-Supported Use

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Conjugated estrogens/bazedoxifene in pediatric patients.

Contraindications

• Condition1

Warnings

WARNING See full prescribing information for complete Boxed Warning. ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA: Women taking DUAVEE should not take additional estrogens There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens Estrogen therapy should not be used for the prevention of cardiovascular disease or dementia The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

• Description

Precautions

• Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Conjugated estrogens/bazedoxifene in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Conjugated estrogens/bazedoxifene in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Drug Interactions

• Drug

• Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

• Pregnancy Category

Pregnancy Category (AUS):

• Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Conjugated estrogens/bazedoxifene in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Conjugated estrogens/bazedoxifene during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Conjugated estrogens/bazedoxifene with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Conjugated estrogens/bazedoxifene with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Conjugated estrogens/bazedoxifene with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Conjugated estrogens/bazedoxifene with respect to specific gender populations.

Race

There is no FDA guidance on the use of Conjugated estrogens/bazedoxifene with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Conjugated estrogens/bazedoxifene in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Conjugated estrogens/bazedoxifene in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Conjugated estrogens/bazedoxifene in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Conjugated estrogens/bazedoxifene in patients who are immunocompromised.

Administration and Monitoring

Administration

• Oral

• Intravenous

Monitoring

There is limited information regarding Monitoring of Conjugated estrogens/bazedoxifene in the drug label.

• Description

IV Compatibility

There is limited information regarding IV Compatibility of Conjugated estrogens/bazedoxifene in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

• Description

Management

• Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Conjugated estrogens/bazedoxifene in the drug label.

Pharmacology

There is limited information regarding Conjugated estrogens/bazedoxifene Pharmacology in the drug label.

Mechanism of Action

Structure

File:Conjugated estrogens/bazedoxifene01.png

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Conjugated estrogens/bazedoxifene in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Conjugated estrogens/bazedoxifene in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Conjugated estrogens/bazedoxifene in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Conjugated estrogens/bazedoxifene in the drug label.

How Supplied

Storage

There is limited information regarding Conjugated estrogens/bazedoxifene Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Conjugated estrogens/bazedoxifene |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Conjugated estrogens/bazedoxifene |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Conjugated estrogens/bazedoxifene in the drug label.

Precautions with Alcohol

• Alcohol-Conjugated estrogens/bazedoxifene interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

• ®

Look-Alike Drug Names

• A® — B®

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject:

 |Page Name=Conjugated estrogens/bazedoxifene
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Conjugated estrogens/bazedoxifene
 |Label Name=Conjugated estrogens/bazedoxifene11.png

}}

{{#subobject:

 |Label Page=Conjugated estrogens/bazedoxifene
 |Label Name=Conjugated estrogens/bazedoxifene11.png

}}